EIF2AK3 and pancreatic neoplasm: Also recruiting, is a Phase Ia clinical trial for HC-5404-FU, another PERK inhibitor, seeking patients with renal cell carcinoma, gastric cancer, metastatic breast cancer, small cell lung cancer, and other solid tumors (except rapidly progressing neoplasms, such as pancreatic cancer) (NCT04834778).